Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration
Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) are retinal degenerative disorders that dramatically damage the retina. As there is no therapeutic option for the majority of patients, vision is progressively and irremediably lost. Owing to their unlimited renewal and potency to...
Gespeichert in:
Veröffentlicht in: | Molecular and cellular neuroscience 2020-09, Vol.107, p.103523-103523, Article 103523 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 103523 |
---|---|
container_issue | |
container_start_page | 103523 |
container_title | Molecular and cellular neuroscience |
container_volume | 107 |
creator | Morizur, Lise Herardot, Elise Monville, Christelle Ben M'Barek, Karim |
description | Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) are retinal degenerative disorders that dramatically damage the retina. As there is no therapeutic option for the majority of patients, vision is progressively and irremediably lost. Owing to their unlimited renewal and potency to give rise to any cell type of the human adult body, human pluripotent stem cells (hPSCs) have been extensively studied in recent years to develop more physiologically relevant in vitro cellular models. Such models open new perspectives to investigate the pathological molecular mechanisms of AMD and RP but also in drug screening. Moreover, proof-of-concept of hPSC-derived retinal cell therapy in animal models have led to first clinical trials. This review outlines the recent advances in the use of hPSCs in pathological modeling of retinal degeneration and their use in regenerative medicine. We also address the associated limitations and challenges that need to be overcome when using hPSCs.
•Pathological mechanisms of AMD and RP are not fully understood.•Patient hPSC derived retinal cells recapitulate the hallmarks of AMD and RP.•AMD/RP hPSC retinal cells could be used for drug screening.•hPSC-RPE cell therapy is currently evaluated in clinical trials.•hPSC derived PR therapy needs improvements before clinical evaluation. |
doi_str_mv | 10.1016/j.mcn.2020.103523 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03492526v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1044743120301469</els_id><sourcerecordid>2421464105</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-dfc9c2107051c11bb46836668b8c4b82a0a132fb05248702ff69cb344e27ec743</originalsourceid><addsrcrecordid>eNp9UMtOwzAQjBBIlMIHcPMRDil-xUngVFVAkSpxKWfLcTbgKrGD7VTw9yQK4shhtQ_NjHYmSa4JXhFMxN1h1Wm7ophOO8soO0kWBJdZWjKan04z52nOGTlPLkI4YIwzWrJFst8OnbKobwdvehfBRhQidEhD24Z7tEbRubZyX2NHg63Bh6hsjaaKHlREHqKxqkU1vIMFr6Jx9jI5a1Qb4Oq3L5O3p8f9ZpvuXp9fNutdqjNKYlo3utSU4BxnRBNSVVwUTAhRVIXmVUEVVoTRphpf5UWOadOIUleMc6A56NHMMrmddT9UK3tvOuW_pVNGbtc7Od0w4yXNqDiSEXszY3vvPgcIUXYmTC6VBTcESTklXHCCsxFKZqj2LgQPzZ82wXJKWx7kmLac0pZz2iPnYebA6PdowMugDVgNtfGgo6yd-Yf9A39FhjI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2421464105</pqid></control><display><type>article</type><title>Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration</title><source>ScienceDirect Freedom Collection (Elsevier)</source><creator>Morizur, Lise ; Herardot, Elise ; Monville, Christelle ; Ben M'Barek, Karim</creator><creatorcontrib>Morizur, Lise ; Herardot, Elise ; Monville, Christelle ; Ben M'Barek, Karim</creatorcontrib><description>Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) are retinal degenerative disorders that dramatically damage the retina. As there is no therapeutic option for the majority of patients, vision is progressively and irremediably lost. Owing to their unlimited renewal and potency to give rise to any cell type of the human adult body, human pluripotent stem cells (hPSCs) have been extensively studied in recent years to develop more physiologically relevant in vitro cellular models. Such models open new perspectives to investigate the pathological molecular mechanisms of AMD and RP but also in drug screening. Moreover, proof-of-concept of hPSC-derived retinal cell therapy in animal models have led to first clinical trials. This review outlines the recent advances in the use of hPSCs in pathological modeling of retinal degeneration and their use in regenerative medicine. We also address the associated limitations and challenges that need to be overcome when using hPSCs.
•Pathological mechanisms of AMD and RP are not fully understood.•Patient hPSC derived retinal cells recapitulate the hallmarks of AMD and RP.•AMD/RP hPSC retinal cells could be used for drug screening.•hPSC-RPE cell therapy is currently evaluated in clinical trials.•hPSC derived PR therapy needs improvements before clinical evaluation.</description><identifier>ISSN: 1044-7431</identifier><identifier>EISSN: 1095-9327</identifier><identifier>DOI: 10.1016/j.mcn.2020.103523</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>Age-related Macular Degeneration ; Cell therapy ; Disease modeling ; Human pluripotent stem cells ; Life Sciences ; Retinitis Pigmentosa ; Retinopathies</subject><ispartof>Molecular and cellular neuroscience, 2020-09, Vol.107, p.103523-103523, Article 103523</ispartof><rights>2020 The Author(s)</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-dfc9c2107051c11bb46836668b8c4b82a0a132fb05248702ff69cb344e27ec743</citedby><cites>FETCH-LOGICAL-c521t-dfc9c2107051c11bb46836668b8c4b82a0a132fb05248702ff69cb344e27ec743</cites><orcidid>0000-0003-1256-5140 ; 0000-0002-2556-0325</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.mcn.2020.103523$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://hal.science/hal-03492526$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Morizur, Lise</creatorcontrib><creatorcontrib>Herardot, Elise</creatorcontrib><creatorcontrib>Monville, Christelle</creatorcontrib><creatorcontrib>Ben M'Barek, Karim</creatorcontrib><title>Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration</title><title>Molecular and cellular neuroscience</title><description>Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) are retinal degenerative disorders that dramatically damage the retina. As there is no therapeutic option for the majority of patients, vision is progressively and irremediably lost. Owing to their unlimited renewal and potency to give rise to any cell type of the human adult body, human pluripotent stem cells (hPSCs) have been extensively studied in recent years to develop more physiologically relevant in vitro cellular models. Such models open new perspectives to investigate the pathological molecular mechanisms of AMD and RP but also in drug screening. Moreover, proof-of-concept of hPSC-derived retinal cell therapy in animal models have led to first clinical trials. This review outlines the recent advances in the use of hPSCs in pathological modeling of retinal degeneration and their use in regenerative medicine. We also address the associated limitations and challenges that need to be overcome when using hPSCs.
•Pathological mechanisms of AMD and RP are not fully understood.•Patient hPSC derived retinal cells recapitulate the hallmarks of AMD and RP.•AMD/RP hPSC retinal cells could be used for drug screening.•hPSC-RPE cell therapy is currently evaluated in clinical trials.•hPSC derived PR therapy needs improvements before clinical evaluation.</description><subject>Age-related Macular Degeneration</subject><subject>Cell therapy</subject><subject>Disease modeling</subject><subject>Human pluripotent stem cells</subject><subject>Life Sciences</subject><subject>Retinitis Pigmentosa</subject><subject>Retinopathies</subject><issn>1044-7431</issn><issn>1095-9327</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9UMtOwzAQjBBIlMIHcPMRDil-xUngVFVAkSpxKWfLcTbgKrGD7VTw9yQK4shhtQ_NjHYmSa4JXhFMxN1h1Wm7ophOO8soO0kWBJdZWjKan04z52nOGTlPLkI4YIwzWrJFst8OnbKobwdvehfBRhQidEhD24Z7tEbRubZyX2NHg63Bh6hsjaaKHlREHqKxqkU1vIMFr6Jx9jI5a1Qb4Oq3L5O3p8f9ZpvuXp9fNutdqjNKYlo3utSU4BxnRBNSVVwUTAhRVIXmVUEVVoTRphpf5UWOadOIUleMc6A56NHMMrmddT9UK3tvOuW_pVNGbtc7Od0w4yXNqDiSEXszY3vvPgcIUXYmTC6VBTcESTklXHCCsxFKZqj2LgQPzZ82wXJKWx7kmLac0pZz2iPnYebA6PdowMugDVgNtfGgo6yd-Yf9A39FhjI</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Morizur, Lise</creator><creator>Herardot, Elise</creator><creator>Monville, Christelle</creator><creator>Ben M'Barek, Karim</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0003-1256-5140</orcidid><orcidid>https://orcid.org/0000-0002-2556-0325</orcidid></search><sort><creationdate>20200901</creationdate><title>Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration</title><author>Morizur, Lise ; Herardot, Elise ; Monville, Christelle ; Ben M'Barek, Karim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-dfc9c2107051c11bb46836668b8c4b82a0a132fb05248702ff69cb344e27ec743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age-related Macular Degeneration</topic><topic>Cell therapy</topic><topic>Disease modeling</topic><topic>Human pluripotent stem cells</topic><topic>Life Sciences</topic><topic>Retinitis Pigmentosa</topic><topic>Retinopathies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morizur, Lise</creatorcontrib><creatorcontrib>Herardot, Elise</creatorcontrib><creatorcontrib>Monville, Christelle</creatorcontrib><creatorcontrib>Ben M'Barek, Karim</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Molecular and cellular neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morizur, Lise</au><au>Herardot, Elise</au><au>Monville, Christelle</au><au>Ben M'Barek, Karim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration</atitle><jtitle>Molecular and cellular neuroscience</jtitle><date>2020-09-01</date><risdate>2020</risdate><volume>107</volume><spage>103523</spage><epage>103523</epage><pages>103523-103523</pages><artnum>103523</artnum><issn>1044-7431</issn><eissn>1095-9327</eissn><abstract>Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) are retinal degenerative disorders that dramatically damage the retina. As there is no therapeutic option for the majority of patients, vision is progressively and irremediably lost. Owing to their unlimited renewal and potency to give rise to any cell type of the human adult body, human pluripotent stem cells (hPSCs) have been extensively studied in recent years to develop more physiologically relevant in vitro cellular models. Such models open new perspectives to investigate the pathological molecular mechanisms of AMD and RP but also in drug screening. Moreover, proof-of-concept of hPSC-derived retinal cell therapy in animal models have led to first clinical trials. This review outlines the recent advances in the use of hPSCs in pathological modeling of retinal degeneration and their use in regenerative medicine. We also address the associated limitations and challenges that need to be overcome when using hPSCs.
•Pathological mechanisms of AMD and RP are not fully understood.•Patient hPSC derived retinal cells recapitulate the hallmarks of AMD and RP.•AMD/RP hPSC retinal cells could be used for drug screening.•hPSC-RPE cell therapy is currently evaluated in clinical trials.•hPSC derived PR therapy needs improvements before clinical evaluation.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.mcn.2020.103523</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-1256-5140</orcidid><orcidid>https://orcid.org/0000-0002-2556-0325</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1044-7431 |
ispartof | Molecular and cellular neuroscience, 2020-09, Vol.107, p.103523-103523, Article 103523 |
issn | 1044-7431 1095-9327 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_03492526v1 |
source | ScienceDirect Freedom Collection (Elsevier) |
subjects | Age-related Macular Degeneration Cell therapy Disease modeling Human pluripotent stem cells Life Sciences Retinitis Pigmentosa Retinopathies |
title | Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T07%3A04%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20pluripotent%20stem%20cells:%20A%20toolbox%20to%20understand%20and%20treat%20retinal%20degeneration&rft.jtitle=Molecular%20and%20cellular%20neuroscience&rft.au=Morizur,%20Lise&rft.date=2020-09-01&rft.volume=107&rft.spage=103523&rft.epage=103523&rft.pages=103523-103523&rft.artnum=103523&rft.issn=1044-7431&rft.eissn=1095-9327&rft_id=info:doi/10.1016/j.mcn.2020.103523&rft_dat=%3Cproquest_hal_p%3E2421464105%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2421464105&rft_id=info:pmid/&rft_els_id=S1044743120301469&rfr_iscdi=true |